Kohei shitara (@KoheiShitara) / X

Por um escritor misterioso
Last updated 30 dezembro 2024
Kohei shitara (@KoheiShitara) / X
Kohei shitara (@KoheiShitara) / X
Jeroen Dekervel (@JDekervel) / X
Kohei shitara (@KoheiShitara) / X
Kohei SHITARA, Chief, Department of Gastrointestinal Oncolology
Kohei shitara (@KoheiShitara) / X
Kohei shitara (@KoheiShitara) / X
Kohei shitara (@KoheiShitara) / X
Kohei shitara on X: Nivolumab monotherapy two dose as NAC for gastric cancer showed 5 patients (16%) with MPR(<10% tumor) including 4 MSI-H and 1 MSS patients. Supporting ongoing perioperative trials.#stomachcancer @OncoAlert
Kohei shitara (@KoheiShitara) / X
Kohei Shitara, Videos & Research
Kohei shitara (@KoheiShitara) / X
Kohei shitara on X: Nivolumab monotherapy two dose as NAC for gastric cancer showed 5 patients (16%) with MPR(<10% tumor) including 4 MSI-H and 1 MSS patients. Supporting ongoing perioperative trials.#stomachcancer @OncoAlert
Kohei shitara (@KoheiShitara) / X
Alexandre Jácome (@AJacomeMD) / X
Kohei shitara (@KoheiShitara) / X
Raghav Sundar (@sundar__raghav) / X
Kohei shitara (@KoheiShitara) / X
OncologyTube - DESTINY-Gastric01 Phase II Study Kohei
Kohei shitara (@KoheiShitara) / X
Raghav Sundar (@sundar__raghav) / X
Kohei shitara (@KoheiShitara) / X
Kohei shitara (@KoheiShitara) / X
Kohei shitara (@KoheiShitara) / X
Kohei shitara (@KoheiShitara) / X
Kohei shitara (@KoheiShitara) / X
Oncology Data Advisor - Zolbetuximab: Gastric/Gastroesophageal Junction Adenocarcinoma
Kohei shitara (@KoheiShitara) / X
Joseph J Zhao (@josephjzhao) / X
Kohei shitara (@KoheiShitara) / X
Daniel Catenacci (@DocCatenacci) / X

© 2014-2024 praharacademy.in. All rights reserved.